Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nephros (NEPH) Gains from Investment Securities (2016 - 2025)

Nephros (NEPH) has 14 years of Gains from Investment Securities data on record, last reported at -$2000.0 in Q3 2025.

  • For Q3 2025, Gains from Investment Securities changed N/A year-over-year to -$2000.0; the TTM value through Sep 2025 reached $4000.0, down 93.1%, while the annual FY2024 figure was $87198.0, 95.13% down from the prior year.
  • Gains from Investment Securities reached -$2000.0 in Q3 2025 per NEPH's latest filing, down from $5000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $168000.0 in Q3 2021 and bottomed at -$2000.0 in Q3 2025.
  • Average Gains from Investment Securities over 5 years is $28413.2, with a median of $5000.0 recorded in 2025.
  • Peak YoY movement for Gains from Investment Securities: tumbled 95.42% in 2021, then soared 500.0% in 2023.
  • A 5-year view of Gains from Investment Securities shows it stood at $58000.0 in 2021, then plummeted by 84.48% to $9000.0 in 2022, then skyrocketed by 500.0% to $54000.0 in 2023, then soared by 61.48% to $87198.0 in 2024, then tumbled by 102.29% to -$2000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were -$2000.0 in Q3 2025, $5000.0 in Q2 2025, and $1000.0 in Q1 2025.